Weiss Ratings Reaffirms Sell (D-) Rating for 2seventy bio (NASDAQ:TSVT)

2seventy bio (NASDAQ:TSVT)‘s stock had its “sell (d-)” rating reaffirmed by Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

2seventy bio Stock Performance

Shares of NASDAQ:TSVT opened at $2.68 on Wednesday. The firm has a 50 day simple moving average of $2.70 and a 200 day simple moving average of $3.84. 2seventy bio has a 52 week low of $2.29 and a 52 week high of $6.00. The company has a market cap of $138.26 million, a PE ratio of -1.44 and a beta of 1.74.

Institutional Trading of 2seventy bio

Hedge funds and other institutional investors have recently modified their holdings of the business. Bank of America Corp DE raised its position in 2seventy bio by 317.1% during the fourth quarter. Bank of America Corp DE now owns 2,515,897 shares of the company’s stock valued at $7,397,000 after buying an additional 1,912,771 shares during the period. Regeneron Pharmaceuticals Inc. purchased a new position in 2seventy bio during the 4th quarter valued at about $3,689,000. Geode Capital Management LLC increased its holdings in shares of 2seventy bio by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,176,244 shares of the company’s stock valued at $5,553,000 after purchasing an additional 13,144 shares during the period. State Street Corp lifted its position in shares of 2seventy bio by 1.5% in the third quarter. State Street Corp now owns 1,058,773 shares of the company’s stock worth $4,997,000 after purchasing an additional 15,638 shares in the last quarter. Finally, Eversept Partners LP lifted its position in shares of 2seventy bio by 0.6% in the fourth quarter. Eversept Partners LP now owns 1,003,678 shares of the company’s stock worth $2,951,000 after purchasing an additional 5,599 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.